The surgical management of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3595-3606

  Udelsman, Robert ^a   Åkerström, Göran ^b   Biagini, Carlo ^c   Duh, Quan Yang ^d   Miccoli, Paolo ^e   Niederle, Bruno ^f   Tonelli, Francesco ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Centro Oncologico Fiorentino   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CALCIUM; LITHIUM ION; THIAZIDE DIURETIC AGENT; VITAMIN D;

ASYMPTOMATIC DISEASE; BIOCHEMISTRY; CASR GENE; CDC73 GENE; CDKN1B GENE; CERVICAL EXPLORATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; ENDOCRINE TUMOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; FAMILY HISTORY; GENE MUTATION; HRPT2 GENE; HUMAN; HYPERPARATHYROIDISM JAW TUMOR; HYPOCALCEMIA; INTRAOPERATIVE GAMMA PROBE; LOCAL ANESTHESIA; MEN 3 GENE; MEN1 GENE; MINIMALLY INVASIVE PROCEDURE; MORTALITY; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; NEUROMONITORING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PARATHYROID SCINTISCANNING; PARATHYROIDECTOMY; PEROPERATIVE COMPLICATION; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT LARYNGEAL NERVE INJURY; REGIONAL ANESTHESIA; RET GENE; RISK BENEFIT ANALYSIS; SAFETY; SIPPLE SYNDROME; SURGICAL APPROACH; SURGICAL EQUIPMENT; SURGICAL RISK; TREATMENT INDICATION; VIDEOENDOSCOPY; WORKSHOP; CONSENSUS DEVELOPMENT; EDUCATION; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINE; STANDARDS;

ASYMPTOMATIC DISEASES; EDUCATION; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINES AS TOPIC;

EID: 84906672825     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2000     Document Type: Conference Paper

References (78)

1. Bilezikian JP. Primary hyperparathyroidism. Endocr Pract. 2012;18:781-790.
2. Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:366-372.
3. Pasieka JL, Parsons LL. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg. 1998;22:513-518; discussion 518-519.
4. Roman SA, Sosa JA, Pietrzak RH, et al. The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg. 2011;253:131-137.
5. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3580-3594.
6. Starker LF, Akerström T, Long WD, et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012;3:44-51.
7. Costa-Guda J, Soong CP, Parekh VI, Agarwal SK, Arnold A. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4:301-307.
8. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-3569.
9. Kunstman JW, Kirsch JD, Mahajan A, Udelsman R. Clinical review: parathyroid localization and implications for clinical management. J Clin Endocrinol Metab. 2013;98:902-912.
10. Gotway MB, Reddy GP, Webb WR, Morita ET, Clark OH, Higgins CB. Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism. Radiology. 2001;218:783-790.
11. De Feo ML, Colagrande S, Biagini C, et al. Parathyroid glands: combination of (99m) Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology. 2000;214:393-402.
12. Reeder SB, Desser TS, Weigel RJ, Jeffrey RB. Sonography in primary hyperparathyroidism: review with emphasis on scanning technique. J Ultrasound Med. 2002;21:539-552; quiz 553-534.
13. Prager G, Czerny C, Ofluoglu S, et al. Impact of localization studies on feasibility of minimally invasive parathyroidectomy in an endemic goiter region. J Am Coll Surg. 2003;196:541-548.
14. Siperstein A, Berber E, Mackey R, Alghoul M, Wagner K, Milas M. Prospective evaluation of sestamibi scan, ultrasonography, and rapid PTH to predict the success of limited exploration for sporadic primary hyperparathyroidism. Surgery. 2004;136:872-880.
15. Klingensmith WC 3rd, Koo PJ, Summerlin A, et al. Parathyroid imaging: the importance of pinhole collimation with both singleand dual-tracer acquisition. J Nucl Med Technol. 2013;41:99-104.
16. Leslie WD, Dupont JO, Bybel B, Riese KT. Parathyroid 99mTcsestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout. Eur J Nucl Med Mol Imaging. 2002;29:1566-1570.
17. Lorberboym M, Minski I, Macadziob S, Nikolov G, Schachter P. Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. J Nucl Med. 2003;44:904-908.
18. Schachter PP, Issa N, Shimonov M, Czerniak A, Lorberboym M. Early, postinjection MIBI-SPECTas the only preoperative localizing study for minimally invasive parathyroidectomy. Arch Surg. 2004;139:433-437.
19. Slater A, Gleeson FV. Increased sensitivity and confidenceof SPECT over planar imaging in dual-phase sestamibi for parathyroid adenoma detection. Clin Nucl Med. 2005;30:1-3.
20. Starker LF, Mahajan A, Björklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2011;18:1723-1728.
21. Mahajan A, Starker LF, Ghita M, Udelsman R, Brink JA, Carling T. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg. 2012;36:1335-1339.
22. Nichols KJ, Tomas MB, Tronco GG, et al. Preoperative parathyroid scintigraphic lesion localization: accuracy of various types of readings. Radiology. 2008;248:221-232.
23. Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg. 2009;209:332-343.
24. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253:585-591.
25. Van Udelsman B, Udelsman R. Surgery in primary hyperparathyroidism: extensive personal experience. J Clin Densitom. 2013;16:54-59.
26. Leder SB, Donovan P, Acton LM, et al. Laryngeal physiology and voice acoustics are maintained after minimally invasive parathyroidectomy. Ann Surg. 2013;257:968-970.
27. Carneiro DM, Solorzano CC, Nader MC, Ramirez M, Irvin GL 3rd. Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery. 2003;134:973-979; discussion 979-981.
28. Henry JF, Sebag F, Cherenko M, Ippolito G, Taieb D, Vaillant J. Endoscopic parathyroidectomy: why and when? World J Surg. 2008;32:2509-2515.
29. Miccoli P, Materazzi G, Baggiani A, Miccoli M. Mini-invasive video-assisted surgery of the thyroid and parathyroid glands: a 2011 update. J Endocrinol Invest. 2011;34:473-480.
30. Gagner M, Rubino F. Endoscopic parathyroidectomy. In: Gagner M, Inabnet WB, eds. Minimally Invasive Endocrine Surgery. Philadelphia: Lippincott Williams and Wilkins; 2002;111-123.
31. Ditkoff BA, Chabot J, Feind C, Lo Gerfo P. Parathyroid surgery using monitored anesthesia care as an alternative to general anesthesia. Am J Surg. 1996;172:698-700.
32. Lo Gerfo P, Ditkoff BA, Chabot J, Feind C. Thyroid surgery using monitored anesthesia care: an alternative to general anesthesia. Thyroid. 1994;4:437-439.
33. Miccoli P, Barellini L, Monchik JM, Rago R, Berti PF. Randomized clinical trial comparing regional and general anaesthesia in minimally invasive video-assisted parathyroidectomy. Br J Surg. 2005;92:814-818.
34. Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg. 2008;248:420-428.
35. Akerström G. Symposium on evidence-based endocrine surgery (3: hyperparathyroidism). World J Surg. 2009;33:2219-2223.
36. Akerström G, Stalberg P. Surgical management of multiglandular parathyroid disease. In: Randolph G, ed. Surgery of the Thyroid and Parathyroid Glands. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2012;620-638.
37. Marti JL, Yang CS, Carling T, et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol. 2012;19:3465-3471.
38. Di Stasio E, Carrozza C, Pio Lombardi C, et al. Parathyroidectomy monitored by intra-operative PTH: the relevance of the 20 min endpoint. Clin Biochem. 2007;40:595-603.
39. Richards ML, Thompson GB, Farley DR, Grant CS. An optimal algorithm for intraoperative parathyroid hormone monitoring. Arch Surg. 2011;146:280-285.
40. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, Cichon S, Nowak W. Evaluation of Halle, Miami, Rome, and Vienna intraoperative iPTH assay criteria in guiding minimally invasive parathyroidectomy. Langenbecks Arch Surg. 2009;394:843-849.
41. Carneiro DM, Irvin GL 3rd, Inabnet WB. Limited versus radical parathyroidectomy in familial isolated primary hyperparathyroidism. Surgery. 2002;132:1050-1054; discussion 1055.
42. Riss P, Kaczirek K, Bieglmayer C, Niederle B. PTH spikes during parathyroid exploration-a possible pitfall during PTH monitoring? Langenbecks Arch Surg. 2007;392:427-430.
43. Riss P, Krall C, Scheuba C, Bieglmayer C, Niederle B. Risk factors for "PTH spikes" during surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2013;398:881-886.
44. Hughes DT, Miller BS, Doherty GM, Gauger PG. Intraoperative parathyroid hormone monitoring in patients with recognized multiglandular primary hyperparathyroidism. World J Surg. 2011;35:336-341.
45. Lombardi CP, Raffaelli M, Traini E, et al. Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease. Langenbecks Arch Surg. 2008;393:639-645.
46. Udelsman R, Donovan P, Shaw C. Cure predictability during parathyroidectomy. World J Surg. 2014;38:525-533.
47. Riss P, Scheuba C, Asari R, Bieglmayer C, Niederle B. Is minimally invasive parathyroidectomy without QPTH monitoring justified? Langenbecks Arch Surg. 2009;394:875-880.
48. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005;257:27-37.
49. Sharma J, Weber CJ. Surgical therapy for familial hyperparathyroidism. Am Surg. 2009;75:579-582; discussion 582-573.
50. Cetani F, Pardi E, Ambrogini E, et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf). 2006;64:146-152.
51. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(suppl 2):N37-N43.
52. Masi G, Barzon L, Iacobone M, et al. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer. 2008;15:1115-1126.
53. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96-102.
54. Stålberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33:2234-2243.
55. Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Rinkes IH. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg. 2011;35:1993-2005.
56. Twigt BA, Scholten A, Valk GD, Rinkes IH, Vriens MR. Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperativeworkup, operative strategy and follow-up. Orphanet J Rare Dis. 2013;8:50.
57. Vander Walde LH, Haigh PI. Surgical approach to the patient with familial hyperparathyroidism. Curr Treat Options Oncol. 2006;7:326-333.
58. Tonelli F, Giudici F, Cavalli T, Brandi ML. Surgical approach in patients with hyperparathyroidism in multiple endocrine neoplasia type 1: total versus partial parathyroidectomy. Clinics (Sao Paulo). 2012;67(suppl 1):155-160.
59. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007;246:1075-1082.
60. Goudet P, Cougard P, Vergès B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples study group. World J Surg. 2001;25:886-890.
61. Pieterman CR, van Hulsteijn LT, den Heijer M, et al. Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. Ann Surg. 2012;255:1171-1178.
62. Kraimps JL, Duh QY, Demeure M, Clark OH. Hyperparathyroidism in multiple endocrine neoplasia syndrome. Surgery. 1992;112:1080-1086; discussion 1086-1088.
63. Scholten A, Schreinemakers JM, Pieterman CR, Valk GD, Vriens MR, Borel Rinkes IH. Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Endocr Pract. 2011;17:7-15.
64. Molatore S, Marinoni I, Lee M, et al. A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat. 2010;31:E1825-E1835.
65. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94:1826-1834.
66. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386:2-15.
67. Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679-3686.
68. Bricaire L, Odou MF, Cardot-Bauters C, et al. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98:E403-E408.
69. Gunn IR, Gaffney D. Clinical and laboratory features of calciumsensing receptor disorders: a systematic review. Ann Clin Biochem. 2004;41:441-458.
70. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit a11 in hypercalcemia and hypocalcemia. NEngl J Med. 2013;368:2476-2486.
71. Nesbit MA, Hannan FM, Howles SA, et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet. 2013;45:93-97.
72. Siilin H, Rastad J, Ljunggren O, Lundgren E. Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab. 2008;93:47-53.
73. Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008;69:713-720.
74. Shepherd JJ, Burgess JR, Greenaway TM, Ware R. Preoperative sestamibi scanning and surgical findings at bilateral, unilateral, or minimal reoperation for recurrent hyperparathyroidism after subtotal parathyroidectomy in patients with multiple endocrine neoplasia type 1. Arch Surg. 2000;135:844-848.
75. Kandil E, Alabbas HH, Lum YW, Tufaro AP. Familial isolated primary hyperparathyroidism with double adenoma. South Med J. 2010;103:236-238.
76. Skandarajah A, Barlier A, Morlet-Barlat N, et al. Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg. 2010;34:1294-1298.
77. Morris LF, Zelada J, Wu B, Hahn TJ, Yeh MW. Parathyroid surgery in the elderly. Oncologist. 2010;15:1273-1284.
78. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236:543-551.